iXensor, the pioneer of mobile health, today announced its “PixoTest® COVID -19 Antigen Self-Test Kit” has been granted by Taiwan FDA for EUA, in response to the recent peak of the epidemic and the new quarantine mandate of 0+7 taking effect on Oct 13th, Taiwan will officially enter the era of “self-initiated epidemic prevention”.
The latest study of variant recombinant proteins has confirmed that PixoTest® Self Test can effectively detect the Omicron subvariant BA.4 and BA.5 recently ravaging the world. Global studies on Covid-19 have shown that the two strains have biological changes that would speed infection with an increased immune escape from previously reported strains. The World Health Organization (WHO) on September 21st further pointed out that BA.5 has accounted for 76.6% of global new cases, and BA.4 for 7.5%.
In response to the rapid changes of the global pandemic and rising demand for self-testing with a gradual easing of border restrictions, iXensor launched its new product, PixoTest® COVID -19 Antigen Self-Test Kit as
- Simple (easy sampling by simple nasal swab)
- Fast (obtaining test results within 15 minutes)
- Reliable (up to 98% accuracy)
- Effective (able to detect BA.4 and BA.5 variants)
Combining the use of PixoHealth Pass App with its self-reporting feature, iXensor’s PixoTest® COVID -19 Antigen Self-Test is leading you to a safe, secured, and peaceful social new normal.